Fibrinolytic function and coronary risk

被引：29

作者：

Juhan-Vague I. ^{[1
]}

Morange P. ^{[1
]}

Alessi M.C. ^{[1
]}

机构：

[1] Laboratoire d'Hématologie, CHU Timone

来源：

Current Cardiology Reports | 1999年 / 1卷 / 2期

关键词：

Arterioscler Thromb Vasc Biol; Human Adipose Tissue; Plasminogen Activator Inhibitor Type; Activator Mass Concentration; Endogenous Fibrinolysis;

D O I：

10.1007/s11886-999-0069-x

中图分类号：

学科分类号：

摘要：

Plasminogen activation potential in the blood is controlled by an equilibrium between plasminogen activators, mainly tissue-type plasminogen activator (t-PA), and inhibitors, mainly plasminogen activator inhibitor (PAI)-1. In cardiovascular practice, imbalance of this fibrinolytic potential is encountered primarily in the insulin-resistance syndrome. This syndrome leads to increased plasma PAI-1 and t-PA antigen levels (reflecting inactive t-PA/PAI-1 complexes) with a consequent decrease in fibrinolytic activity. Increased plasma PAI-1 and t-PA antigen both are predictive of myocardial infarction. The prognostic value of PAI-1 disappears after adjustments for insulin resistance markers, whereas the prognostic value of t-PA antigen disappears after simultaneous adjustments for insulin resistance and inflammation markers, suggesting an additive role of inflammation in inducing plasma fibrinolytic markers. Recently the production of PAI-1 by adipose tissue, in particular by tissue from the omentum, has been shown. PAI-1 produced in this way could be an important contributor to the elevated plasma PAI-1 levels observed in insulin-resistant patients. These results support the notion that PAI-1 may be a link between obesity, insulin resistance, and cardiovascular disease. Genetic control of PAI-1 expression has also been shown, involving a - 675 4G/5G polymorphism, the 4G/4G genotype being associated with higher plasma PAI-1 levels; its proper influence on the development of myocardial infarction is still debated. Copyright © 1999 by Current Science Inc.

引用

页码：119 / 124

页数：5

共 70 条

[21]

Munkvad S., Gram J., Jespersen J., A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction, Eur Heart J, 11, pp. 525-528, (1990)

[22]

Cortellaro M., Cofrancesco E., Boschetti C., Et al., Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-control study, Arterioscler Thromb, 13, pp. 1412-1417, (1993)

[23]

Thompson S.G., Kienast J., Pyke S.D.M., Et al., Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, N Engl J Med, 332, pp. 635-641, (1995)

[24]

Juhan-Vague I., Pyke S.D.M., Alessi M.C., Et al., Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, Circulation, 94, pp. 2057-2063, (1996)

[25]

Held C., Hjemdhal P., Rehnqvist N., Et al., Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol, Circulation, 95, pp. 2380-2386, (1997)

[26]

Juhan-Vague I., Alessi M.C., Vague P., Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis, Diabetologia, 34, pp. 457-462, (1991)

[27]

Juhan-Vague I., Thompson S.G., Jespersen J., Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris, Arterioscler Thromb, 13, pp. 1865-1873, (1993)

[28]

Potter Van Loon B.J., Kluft C., Radder J.K., Et al., The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance, Metabolism, 42, pp. 945-949, (1993)

[29]

McGill J.B., Schneider D.J., Arfken C.L., Et al., Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients, Diabetes, 43, pp. 104-109, (1994)

[30]

Nagi D.K., Hendra T.J., Ryle A.J., Et al., The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects, Diabetologia, 33, pp. 532-537, (1990)

← 1 2 3 4 5 6 7 →